New drug trial aims to harden less skin in scleroderma
NCT ID NCT07047690
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 30 times
Summary
This study tests a drug called nemolizumab in 162 adults with systemic sclerosis (a disease that causes skin hardening and organ damage). The goal is to see if it safely reduces skin thickness and helps lung function over 52 weeks. Participants receive either the drug or a placebo, and the best dose will be chosen for future studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Galderma Investigational Site # 6213
RECRUITINGSankt Gallen, 9007, Switzerland
Contact
-
Galderma Investigational Site # 8743
RECRUITINGAnn Arbor, Michigan, 48109-5000, United States
Contact
-
Galderma Investigational Site#7096
RECRUITINGArlington, Texas, 76012, United States
Contact
Conditions
Explore the condition pages connected to this study.